V Square Quantitative Management LLC Has $13.66 Million Stake in Johnson & Johnson $JNJ

V Square Quantitative Management LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.0% during the first quarter, HoldingsChannel.com reports. The firm owned 55,896 shares of the company’s stock after buying an additional 2,142 shares during the period. Johnson & Johnson accounts for about 1.4% of V Square Quantitative Management LLC’s investment portfolio, making the stock its 9th largest holding. V Square Quantitative Management LLC’s holdings in Johnson & Johnson were worth $13,663,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Blueline Advisors LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $25,000. Cresta Advisors Ltd. bought a new position in Johnson & Johnson during the fourth quarter worth about $26,000. DecisionPoint Financial LLC lifted its stake in Johnson & Johnson by 104.2% during the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after purchasing an additional 75 shares during the period. Family CFO Inc acquired a new stake in Johnson & Johnson during the fourth quarter valued at approximately $31,000. Finally, Bay Harbor Wealth Management LLC grew its stake in shares of Johnson & Johnson by 49.0% in the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock valued at $31,000 after purchasing an additional 49 shares during the period. 69.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

JNJ has been the topic of several recent analyst reports. Stifel Nicolaus boosted their price target on Johnson & Johnson from $220.00 to $250.00 and gave the company a “hold” rating in a research note on Wednesday, April 15th. Barclays lifted their price objective on Johnson & Johnson from $234.00 to $255.00 and gave the company an “equal weight” rating in a report on Wednesday, April 15th. The Goldman Sachs Group boosted their target price on shares of Johnson & Johnson from $265.00 to $275.00 and gave the company a “buy” rating in a research note on Wednesday, April 15th. Royal Bank Of Canada reiterated an “outperform” rating and set a $265.00 target price on shares of Johnson & Johnson in a research report on Wednesday, April 15th. Finally, Weiss Ratings downgraded shares of Johnson & Johnson from a “buy (b)” rating to a “buy (b-)” rating in a report on Monday, June 15th. Twenty investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $257.13.

Insider Activity at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the sale, the executive vice president directly owned 114,288 shares of the company’s stock, valued at $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $267.35 on Wednesday. The business’s fifty day moving average is $235.09 and its two-hundred day moving average is $232.13. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. The firm has a market cap of $643.56 billion, a P/E ratio of 30.91, a P/E/G ratio of 2.54 and a beta of 0.24. Johnson & Johnson has a 52 week low of $154.21 and a 52 week high of $269.43.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.02. The business had revenue of $24.06 billion during the quarter, compared to analysts’ expectations of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period in the previous year, the business posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Equities research analysts forecast that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th were given a dividend of $1.34 per share. The ex-dividend date was Tuesday, May 26th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 61.97%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Investors are buying JNJ ahead of earnings, helped by a higher company outlook, a recent analyst price-target increase, and expectations for another solid quarter. Johnson & Johnson (JNJ) Could Be 34% Below Fair Value Following IMAAVY Update
• Positive Sentiment: Wall Street commentary says JNJ’s recent record run reflects rising price targets and strong institutional buying, reinforcing the bullish view on the stock. Johnson & Johnson (JNJ) Stock Surges Past Record High as Wall Street Raises Price Targets
• Positive Sentiment: Analysts expect J&J to report higher second-quarter earnings, which is helping sentiment into the July 15 earnings release. Johnson & Johnson Likely To Report Higher Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
• Neutral Sentiment: Recent articles continue to frame Johnson & Johnson as a defensive healthcare name with dependable dividend income, which may support holding interest but is not a direct catalyst. Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
• Negative Sentiment: One market note highlighted unusual put option activity after JNJ’s runup, suggesting some traders are positioning for a pullback or near-term volatility. Unusual Put Option Activity in Johnson & Johnson After JNJ Stock’s Recent Runup

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.